Report Tackles Changing Landscape For Alzheimer's Diagnostics
MedPredict has published "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.
"Given the size of this patient population and the lack of approved therapeutics for long-term disease control, it is not surprising to see the large number of companies racing to bring Alzheimer's drugs to market," notes MedPredict president Jeff Berk. "Our panel of experts attempts to sort through the hype, and identify the approaches with the most promising early data." Dr. Berk conducted in-depth interviews with a panel of leading experts in Alzheimer's disease as the basis for this report.
In this report, the panel reviews major developments this past year and forecasts the changes they expect to see in the Alzheimer's competitive landscape in 2008. Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence.
These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more.
In addition to the drugs highlighted as most interesting by the experts, this report offers a "program guide" of new compounds, reflecting the many and varied mechanisms being pursued to approach diagnosis and treatment of this disease.